Abstract
CYP2D6 is an enzyme that is subject to genetic polymorphism 1. This P450 is absent in individuals with the poor metabolizer CYP2D6 phenotype 2, 3), resulting in a substantially reduced capacity to metabolize a large number of clinically useful drugs, including metoprolol, propafenone, haloperrdol, dextromethorphan and codeine (1). Quinidine competrtively inhibits CYP2D6, with a K1 of 3-30 mM (3–5). Because of its preferential inhibition of CYP2D6 (6 7), quinidine is frequently used as an inhibitory chemical probe of this polymorphically expressed P450. Diagnostic catalytic monitors of human hepatic CYP2D6 include debrisoquine 4-hydroxylase (4), dextromethorphan Odemethylase (8), and bufuralol l’-hydroxylase activities (2–4). Advantages of using bufuralol as a CYP2D6-selective substrate include the high sensitivity of the assay owing to the highly fluorescent l’-hydroxybufuralol metabohte and the fact that the use of radiolabeled substrate is not required. This chapter describes a modification of a reversed-phase ion-pair high-performance liquid chromatographic (HPLC) assay (9) with fluorescence detection for the determmation of bufuralol l’-hydroxylation activity. Methods for other CYP2D6 assays such as debrisoquine 4-hydroxylase (9) and dextromethorphan O-demethylase (9, 10) can be found in the cited references.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bertilsson, L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CUP) 2D6 and 2C19 Clin Pharmacokinet 29, 192–209
Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M, Zanger, U M., Nebert, D W., Gelboin, H V., Hardwick, J P, and Meyer, U. A. (1988) Characterization of the common genetic defect in humans deficient in debrisoqume metabolism. Nature 331, 442–446
Zanger, U. M., Vilbois, F., Hardwick, J. P., and Meyer, U. A (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoqume oxtdation in man. Biochemistry 27, 5447–5454.
Gut, J, Catin, T, Dayer, P, Kronbach, T., Zanger, U., and Meyer, U. A (1986) Debrisoqume/sparteine-type polymorphism of drug oxidation Purification and charactertzation of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261, 11,734–11,743.
Dayer, P., Kronbach, T., Eichelbaum, M., and Meyer, U. A (1987) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation Characterization of bufuralol l’-hydroxylation in liver microsomes of in VEVO phenotyped carriers of the genetic deficiency. Biochem Pharmacol 36, 4145–4152.
Newton, D. J., Wang, R. W., and Lu, A. Y. H (1995) Cytochrome P450 inhibitors. Evaulatton of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes Drug Metab Dispos 23, 154–158
Bourrie, M., Meumer, V., Berger, Y., and Fabre, G. (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp. Ther 277, 321–332
Dayer, P., Leemann, T, and Striberni, R (1989) Dextromethorphan Odemethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 dbl activity. Clin. Pharmacol. Ther 45, 34–40.
Kronbach, T., Mathys, D., Gut, J., Catin, T, and Meyer, U A (1987) Highperformance liquid chromatographtc assays for bufuralol I’-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver Anal. Biochem. 162, 24–32.
Rodrigues, A. D. (1996) Measurement of human liver microsomal cytochrome P4502D6 activity using [O-methyl-14C]dextromethorphan as substrate. Methods Enzymol. 272, 186–195.
Pearce, R E., McIntyre, C. J, Madan, A., Sanzgni, U, Draper, A. J, Bullock, P L., Cook, D C., Burton, L A, Latham, J., Nevins, C, and Parkmson, A (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys. 331, 145–169
Crespi, C L., Gonzalez, F. J., Steimel, D. T, Turner, T. R., Gelbom, H. V., Penman, B W., and Langenbach, R. (1991) A tobacco smoke-derived nitrosamme, 4-(methylnitrosammo)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytohrome P450s including the polymorphic cytochrome P4502D6. Carcinogeneszs 12, 1197–1201
Yamazaki, H., Guo, Z., Persmark, M., Mimura, M, Inoue, K., Guengerich, F P, and Shimada, T. (1994) Bufuralol hydroxylation by cytochrome P4502D6 and lA2 enzymes in human liver microsomes. Mol. Pharmacol. 46, 568–577
Gillam, E. M. J., Guo, Z., Martin, M. V., Jenkins, C. M., and Guengerich, F P. (1995) Expression of cytochrome P4502D6 in Escherwhia colz, purification, and spectral and catalytic characterization. Arch Biochem Blophys. 319, 540–550
Paine, M. J. I., Gilham, D., Roberts, G. C. K., and Wolf, C. R (1996) Functional high level expression of cytochrome P450 CYP2D6 using baculovirus expression systems. Arch. Biochem. Biophys. 328, 143–150.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Humana Press Inc.
About this protocol
Cite this protocol
L. Crespi, C., K. H. Chang, T., J. Waxman, D. (1998). CYP2D6-Dependent Bufuralol 1’-Hydroxylation Assayed by Reversed-Phase lon-Pair High-Performance Liquid Chromatography with Fluorescence Detection. In: Phillips, I.R., Shephard, E.A. (eds) Cytochrome P450 Protocols. Methods in Molecular Biology™, vol 107. Humana Press. https://doi.org/10.1385/0-89603-519-0:141
Download citation
DOI: https://doi.org/10.1385/0-89603-519-0:141
Publisher Name: Humana Press
Print ISBN: 978-0-89603-519-5
Online ISBN: 978-1-59259-580-8
eBook Packages: Springer Protocols